Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Fox

Showing results (11-20 of 256) with videos related to

Pageof 26
Sort By:
Neurology|March 5, 2010
Primary neuroprotection: the Holy Grail of multiple sclerosis therapyRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2013
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yesRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2016
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NORobert J Fox
Neurology|April 17, 2015
Comment: A better measuring stick for walking in multiple sclerosisRobert J Fox
Archives of Neurology|April 12, 2006
Defending eponymsRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 8, 2015
Disability progression in relapsing MS is more than just lesions: The lesson of fingolimodRobert J Fox
The Lancet. Neurology|January 30, 2016
Refining diagnosis of multiple sclerosis with revised MRI criteriaRobert J Fox
Neurology. Clinical Practice|February 24, 2018
Dimethyl fumarate for relapsing MSAlessandro Serra, Robert J Fox
Neurology. Clinical Practice|January 30, 2018
Long-term registries: Answering tough questions with big data?Robert J Fox, Gary Cutter
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2017
Advancing trial design in progressive multiple sclerosisRobert J Fox, Jeremy Chataway
Pageof 26

Showing results (11-20 of 256) with videos related to

Sort By:
Pageof 26
Neurology|March 5, 2010
Primary neuroprotection: the Holy Grail of multiple sclerosis therapyRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2013
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yesRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2016
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NORobert J Fox
Neurology|April 17, 2015
Comment: A better measuring stick for walking in multiple sclerosisRobert J Fox
Archives of Neurology|April 12, 2006
Defending eponymsRobert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 8, 2015
Disability progression in relapsing MS is more than just lesions: The lesson of fingolimodRobert J Fox
The Lancet. Neurology|January 30, 2016
Refining diagnosis of multiple sclerosis with revised MRI criteriaRobert J Fox
Neurology. Clinical Practice|February 24, 2018
Dimethyl fumarate for relapsing MSAlessandro Serra, Robert J Fox
Neurology. Clinical Practice|January 30, 2018
Long-term registries: Answering tough questions with big data?Robert J Fox, Gary Cutter
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2017
Advancing trial design in progressive multiple sclerosisRobert J Fox, Jeremy Chataway
Pageof 26